GlassScriptPhysician profile
Anthony Alatriste
NPI 1689603383
$2,324.44
in general payments reported to CMS, 2019-2025
29 companies · $646 in 2025
The $646 reported for 2025 was more than what 85% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
See the full distribution for Geriatric Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $215 · 2021: $203 · 2022: $411 · 2023: $353 · 2024: $310 · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,310.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $401.87 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Evoke Pharma, INC. | $401.54 | 2021-2025 | Gimoti |
| Novo Nordisk INC | $163.29 | 2019-2025 | Ozempic |
| Lilly USA, LLC | $161.19 | 2022-2025 | Mounjaro, Jardiance, Amyvid |
| Bayer Healthcare Pharmaceuticals INC. | $124.07 | 2022-2025 | |
| Amgen INC. | $105.44 | 2019-2025 | Otezla, Repatha, Otezla |
| Almatica Pharma LLC | $100.74 | 2024-2025 | Loreev Xr |
| Abbott Laboratories | $82.23 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $78.40 | 2021-2023 | Xarelto |
| Exact Sciences Corporation | $77.12 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.66 | 2022-2025 | Relistor, Xifaxan |
| Abbvie INC. | $58.69 | 2022-2024 | |
| Idorsia Pharmaceuticals US INC | $48.51 | 2022-2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.54 | 2019 | |
| Genentech USA, INC. | $45.42 | 2020-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $42.05 | 2022-2023 | Seglentis |
| Boston Scientific Corporation | $41.26 | 2019-2020 | |
| Melinta Therapeutics, LLC | $36.11 | 2025 | Kimyrsa |
| Paratek Pharmaceuticals, INC. | $34.14 | 2023-2025 | Nuzyra, Xhance |
| Merck Sharp & Dohme LLC | $30.14 | 2020 | |
| Aytu Biopharma, INC. | $27.53 | 2019-2020 | |
| Allergan, INC. | $25.31 | 2020 | |
| Corcept Therapeutics | $20.02 | 2019 | |
| Smith+Nephew, INC. | $19.27 | 2024 | Collagenase Santyl |
| Axsome Therapeutics, INC. | $18.79 | 2023 | Auvelity |
| Acerus Pharmaceuticals Corporation | $16.39 | 2021 | |
| Phadia US INC. | $15.56 | 2025 | Immunocap |
| Inari Medical, INC. | $14.85 | 2021 | |
| Astellas Pharma US INC | $14.31 | 2023 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Alatriste listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.